Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

M-CSF as a therapeutic target in BRAFV600E melanoma resistant to BRAF inhibitors.

British journal of cancer - 1 Oct 2022

Barceló C, Sisó P, de la Rosa I, Megino-Luque C, Navaridas R, Maiques O, Urdanibia I, Eritja N, Soria X, Potrony M, Calbet-Llopart N, Puig S, Matías-Guiu X, Martí R M, Macià A

Abstract excerpt

BACKGROUND: Disseminated BRAFV600E melanoma responds to BRAF inhibitors (BRAFi) but easily develops resistance with poor prognosis. Secretome plays a pivotal role during tumour progression causing profound effects on therapeutic efficacy. Secreted M-CSF is involved in both cytotoxicity suppression and tumour progression in melanoma. We aimed to analyse the M-CSF contribution in resistant metastatic melanoma to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to Indoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Macrophage Colony-Stimulating Factor

Share to Melanoma

Share to Mice, SCID

Share to Proto-Oncogene Proteins B-raf

Share to Sulfonamides

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 35725813
DOI: 10.1038/s41416-022-01886-4
PMCID: PMC9470708

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

M-CSF as a therapeutic target in BRAFV600E melanoma resistant to BRAF inhibitors.PMID 35725813Read ↗

Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanomaSemantic proximity Read ↗

BRAFV600 inhibition alters the microRNA cargo in the vesicular secretome of malignant melanoma cells.Semantic proximity Read ↗

Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis.Semantic proximity Read ↗

Role of VEGFR-1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib.Semantic proximity Read ↗

Adverse prognosis of GM-CSF expression in human cutaneous melanomaSemantic proximity Read ↗

Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma.Semantic proximity Read ↗

Transcripts 202 and 205 of IL-6 confer resistance to Vemurafenib by reactivating the MAPK pathway in BRAF(V600E) mutant melanoma cells.Semantic proximity Read ↗

Large extracellular vesicles regulate endothelial angiogenic potential via paracrine and autocrine signalingSemantic proximity Read ↗

Vemurafenib and trametinib reduce expression of CTGF and IL-8 in V600EBRAF melanoma cells.Semantic proximity Read ↗

CDDO-Methyl Ester Inhibits BRAF Inhibitor Resistance and Remodels the Myeloid Compartment in BRAF-mutant MelanomaSemantic proximity Read ↗

An autophagy-driven pathway of ATP secretion supports the aggressive phenotype of BRAFV600E inhibitor-resistant metastatic melanoma cells.Semantic proximity Read ↗

PTRF Confers Melanoma‐Acquired Drug Resistance Through the Upregulation of EGFRSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.